Full Breakdown
Advancements in Genetic Testing for Heart Rhythm Disorders
11/18/2025, 8:38:34 PM
New Genetic Approach to Predicting Arrhythmias
Researchers at Northwestern Medicine have developed a refined genetic risk score that enhances the prediction of arrhythmias, conditions characterized by irregular heartbeats that can lead to serious health issues such as atrial fibrillation (AFib) and sudden cardiac death. This innovative study, published on November 11 in *Cell Reports Medicine*, integrates monogenic and polygenic testing methods, which have traditionally been used separately in both research and clinical settings. By analyzing data from 1,119 participants, the study aims to create targeted treatments tailored to individual genetic profiles.
Integrating Genetic Testing Methods
The research team combined three major genetic testing approaches: monogenic testing, which identifies rare mutations in single genes; polygenic testing, which assesses many common gene variants to estimate overall risk; and whole genome sequencing, which reads the complete genetic code. Dr. Elizabeth McNally, co-corresponding author and director of the Center for Genetic Testing at Northwestern University Feinberg School of Medicine, emphasized the uniqueness of this comprehensive approach, stating, “It’s a very cool approach in which we are combining rare gene variants with common gene variants and then adding in non-coding genome information.”
Methodology and Findings
The study involved enrolling 523 individuals diagnosed with arrhythmias, some of whom also had heart failure. Researchers meticulously reviewed medical records and sequenced each participant's genome, calculating a risk score through both monogenic and polygenic testing. The results were then compared to those of 596 control participants from the NUgene biobank, who were aged 40 or older and had no known cardiac disease. McNally noted the rigorous process of confirming participant eligibility, stating, “It was painstaking going through 500-plus records.”
Implications for Clinical Practice
The findings suggest that this integrated genetic approach could significantly improve the identification of individuals at high risk for arrhythmias. Cardiologists typically assess heart risk based on symptoms and family history, but McNally advocates for the inclusion of genetic testing in patient evaluations to better manage care. “Knowledge is power,” she remarked, highlighting the potential for genetic insights to inform treatment decisions, such as recommending defibrillators for high-risk patients.
Challenges and Future Directions
Despite the promising results, genetic testing remains underutilized, with only an estimated 1 to 5% of individuals who could benefit actually receiving it. McNally pointed out that even in cancer care, where genetic links are well-established, only 10 to 20% of eligible patients undergo testing. She emphasized the need for improved uptake and training within the medical workforce to leverage genetic testing effectively. As polygenic risk scores gain traction, the integrated approach developed in this study may become increasingly valuable in clinical settings.
Verbatim Quotes
- “We need to improve uptake," McNally said.” — Dr. Elizabeth McNally, Director, Center for Genetic Testing
This study represents a significant step forward in the integration of genetic testing methods, potentially transforming the landscape of cardiac care and risk assessment.
